Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopaminergic Modulation of Frontostriatal Function
NCT02929485Phase 4Withdrawn
- Sponsor
- University of California, Berkeley
- Start
- Jul 2013
- Primary completion
- Jan 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial in substance use disorder (SUD) comparing Tolcapone, Placebo and Bromocriptine (3 arms). Primary endpoints: Effects of Placebo, Tolcapone, Bromocriptine on Reaction Time at 3 weeks and Effects of Placebo, Tolcapone, Bromocriptine on Accuracy at 3 weeks. Planned start Jul 2013; status: withdrawn.
02
Drugs
tolcaponebromocriptine
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT02929485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929485.